Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
OBJECTIVE No large controlled trials have evaluated adjunctive maintenance treatment with long-acting injectable antipsychotics in patients with bipolar disorder . This study assessed whether adjunctive maintenance treatment with risperidone long-acting therapy ( RLAT ) , added to treatment-as-usual ( TAU ) medications for bipolar disorder , delays relapse in patients with bipolar disorder type I. METHODS This study included patients with bipolar disorder type I with > or = four mood episodes in the 12 months prior to study entry . Following a 16-week , open-label stabilization phase with RLAT plus TAU , remitted patients entered a 52-week , double-blind , placebo-controlled , relapse-prevention phase . R and omized patients continued treatment with adjunctive RLAT ( 25 - 50 mg every two weeks ) plus TAU ( n = 65 ) or switched to adjunctive placebo injection plus TAU ( n = 59 ) . The primary outcome measure was time to relapse to any mood episode . RESULTS Of 240 enrolled patients , 124 entered double-blind treatment . Time to relapse was longer in patients receiving adjunctive RLAT ( p = 0.010 ) . Relapse rates were 23.1 % ( n = 15 ) with adjunctive RLAT versus 45.8 % ( n = 27 ) with adjunctive placebo ; relative relapse risk was 2.3-fold higher with adjunctive placebo ( p = 0.011 ) . Completion rates were : adjunctive RLAT , 60.0 % ( n = 39 ) and adjunctive placebo , 42.4 % ( n = 25 ; p = 0.050 ) . Adverse event (AE)-related discontinuations were 4.6 % ( n = 3 ) and 1.7 % ( n = 1 ) , respectively . Common AEs ( adjunctive RLAT versus adjunctive placebo ) were : tremor ( 24.6 % versus 10.2 % ) , insomnia ( 20.0 % versus 18.6 % ) , muscle rigidity ( 12.3 % versus 5.1 % ) , weight increased ( 6.2 % versus 1.7 % ) , and hypokinesia ( 7.7 % versus 0.0 % ) . CONCLUSIONS Adjunctive RLAT significantly delayed time to relapse in patients with bipolar disorder type I who relapse frequently . Safety and tolerability of RLAT were generally consistent with that previously observed
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .